Serum and glucocorticoid-inducible kinase 1 (SGK1) in NSCLC therapy

I Guerriero, G Monaco, V Coppola, A Orlacchio - Pharmaceuticals, 2020 - mdpi.com
Non-small cell lung cancer (NSCLC) remains the most prevalent and one of the deadliest
cancers worldwide. Despite recent success, there is still an urgent need for new therapeutic …

The importance of precision medicine in modern molecular oncology

Y Wang, D Zheng - Clinical Genetics, 2021 - Wiley Online Library
With the rapid development of modern medical technology, information data modeling has
been gradually applied to clinical diagnosis and treatment. Precision medicine is an …

[HTML][HTML] Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC

L Lara-Mejía, AF Cardona, L Mas, C Martin… - Journal of Thoracic …, 2024 - Elsevier
Introduction ALK tyrosine kinase inhibitors have exhibited promising activity against
advanced ALK-rearranged NSCLC. However, co-occurring genetic alterations, such as …

Molecular pathology of cancer: the past, the present, and the future

L Müllauer - Journal of Personalized Medicine, 2021 - mdpi.com
Clinical pathology developed from the study of macroscopic organ and tissue changes at
autopsies [1]. The first Institutes of Pathology emerged in the first half of the 19th century. The …

[PDF][PDF] La gestione del tumore al polmone non a piccole cellule (NSCLC) ALK positivo–l'esperienza dell'Azienda USL Toscana Nord-Ovest The management of ALK+ …

A Camerini, C Caparello, MC Pennucci, M Rotellini… - academia.edu
La traslocazione del gene ALK (anaplastic lymphoma kinase) è un driver oncogenico di
importanza basilare nel trattamento del carcinoma polmonare non a piccole cellule …